Clinical Observation of Botulinum Toxin Injection in the Treatment of Focal Dystonia and Muscle Spasm.

Abstract

Dystonia and muscle spasms are a group of common and unfavorable clinical neurological symptoms. The use of botulinum toxin (BTX-A) abroad has achieved good results in the treatment of various movement disorders characterized by involuntary or abnormal muscle contractions. It is expected to open up a new field for the treatment of myelodysplastic syndromes (MDs) such as focal dystonia and muscle spasm. There are theoretical and practical implications for the diagnosis and development of some effective neurological treatments. The efficacy of BTX-A in the treatment of various focal dystonia and muscle spasm disorders is as follows: symptoms were improved to varying degrees after injection of Botox or botulinum toxin type A (CBTX-A), but Botox or CBTx. There was no significant difference in the efficacy of A. 30.4% of patients had complete remission, 57.8% had significant remission, and 8.9% had partial remission. Among them, HFS and BS had the best curative effect, and the symptoms were significantly improved by 95.3% and 89.4%, respectively. The efficacy of CD was also satisfactory, with 75.5% of the patients showing significant improvement in symptoms, followed by Meg/OMD (OMD) with 73.3% and SD with 3.3%. The efficacy of WC is poor, and functional improvement is uncertain. Other forms of focal dystonia and spasticity also showed significant functional improvement in 60% of patients. Most patients start to see effects within 1 week after BTX-A injection, symptoms gradually improve, and the bridge of curative effect is reached in 2-4 weeks, and the healing effect lasts for about 3-5 months on average. The overall severity of adverse effects was not severe and resolved spontaneously within a few days to ten weeks, with the most concerning complications being ptosis and dysphagia.

• Authors: Zhen Zhang
• Journal: BioMed research international (Biomed Res Int) Vol. 2022 Pg. 1495807 ( 2022) ISSN: 2314-6141 [Electronic] United States
• PMID: 36105931 (Publication Type: Journal Article, Retracted Publication)
• Copyright: Copyright © 2022 Zhen Zhang.

Chemical References

• Botulinum Toxins, Type A

Topics

• Botulinum Toxins, Type A (therapeutic use)
• Dystonia (drug therapy)
• Dystonic Disorders (drug therapy)
• Humans
• Spasm (drug therapy)
• Treatment Outcome